Optic Neuritis Clinical Trials

Find Optic Neuritis Clinical Trials Near You

A Real-World Practical Model of Integrated Management for Chinese Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) on Satralizumab

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: f
View:

• Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody, ≥ 12 years old;

• EDSS score ≤ 8.5 at baseline;

• Patients have experienced ≥ 1 relapse of NMOSD in the last 12 months or ≥ 2 relapses in the last 24 months;

• Patients should have received or be anticipated to receive satralizumab treatment for at least 12 months;

• Patients understand the study procedures and sign the informed consent form indicating willingness to participate in the study (for those \< 18 years of age, the guardian should sign the informed consent form on behalf of the patient).

Locations
Other Locations
China
Huashan Hospital
RECRUITING
Shanghai
Contact Information
Primary
Chao Quan, Doctor
chao_quan@fudan.edu.cn
+8613651957283
Backup
Wenjuan Huang, Doctor
drhuangwenjuan@163.com
+8619921296182
Time Frame
Start Date: 2025-03-31
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 100
Treatments
Satralizumab treatment group
Sponsors
Leads: Huashan Hospital

This content was sourced from clinicaltrials.gov